1. Educational Experience
2001-2004 China Pharmaceutical University, Ph. D in Pharmaceutics
1998-2001 China Pharmaceutical University, Master in Pharmaceutics
1992-1997 China Pharmaceutical University, Bachelor in Pharmacology
2. Working Experience
(1) 2018/08-2019/07, Deputy Director of Gaochun District Science and Technology Bureau of Nanjing City (temporary post)
(2) 2014/08-2015/08, Visiting Scholar, School of Human Ecology, Cornell University, USA
(3) 2008/12-present, Associate Professor, School of Pharmacy, China Pharmaceutical University
(4) 2004/07-2008/11, lecturer, School of Pharmacy, China Pharmaceutical University
Novel drug delivery system of biotechnology drugs;
Novel inhalation drug delivery system and devices;
Novel dosage forms and their pharmacological mechanism.
1. Research Projects
（1）National Science and Technology Major Project. New Dosage Forms and New Controlled-release System Technology Platform. 2009.1-2010.12. Completed.
（2）Study on Preparation Technology and Quality Control of Houttuynia cordata Volatile Oil CD Inclusion Compound Eye Drops. Other provincial and ministerial level projects, 2018.12-2020.11. Completed.
（3）Study on Tea Tree Oil Quantitative Aerosol Film Formulation Band-Aid. 2014.8-2016.8. Completed.
（4）Study on solving the irritation problem of gentamicin diclofenac sodium eye drops. 2017.1-2022.1. Completed.
（5）Development of highly effective anti-inflammatory plant essential oils and related products. 2020.11-2025.11. In progress.
2. Patents
（1）Patent :Application of interleukin-2 as a drug for the treatment of rhinitis,Authorization Number:CN 101125199B,Classification:Patent of invention,Rank:lst,Authorization Time:2010.07.21,Authorization Country:China.
（2）Patent :A dry powder inhalation device,Authorization Number:CN 203458653U,Classification:Model utility,Rank:lst,Authorization Time:2014.03.05,Authorization Country:China.
（3）Patent :A multi dose storage type dry powder inhalation device,Authorization Number:CN2142323338U,Classification:Model utility,Rank:lst,Authorization Time:2021.9.21,Authorization Country:China.
3. Textbook and monograph
（1）Pharmaceutics of Biotechnology Drugs,Year:2018,Publication Number:ISBN 978-7-117-25024-5/R,Press:People's Medical Publishing House,Job:First Editor in Chief.
（2）Modern Biopharmaceutics,Year:2011,Publication Number:ISBN 9787117140539,Press:People's Medical Publishing House,Job:Editorial Board.
（3）Biopharmaceutics Experiment and Guidance,Year:2007,Publication Number:ISBN 978-7-5067-3758-6,Press:China Pharmaceutical Science and Technology Press,Job:Editorial Board.
1. Jing Chen, Yushun Dou, Yue Tang*, Xinru Zhang. Folate receptor-targeted RNAi nanoparticles for silencing STAT3 in tumor-associated macrophages and tumor cells[J]. Nanomedicine 2020, 25:102173.
2. Yue Tang*, Yun Liu, Yuwen Xie, Jing Chen, Yushun Dou. Apoptosis of A549 cells by small interfering RNA targeting survivin delivery using poly-β-amino ester/guanidinylated O-carboxymethyl chitosan nanoparticles[J]. Asian Journal of Pharmaceutical Sciences 2020, 15(1):121-128.
3. Yun Liu, Jing Chen, Yue Tang*, Shuhan Li, Yushun Dou, Jiewen Zheng. Synthesis and characterization of quaternized poly(β-amino ester) for highly efficient delivery of small interfering RNA[J]. Molecular Pharmaceutics, 2018,15(10):4558- 4567.
4. Suhui Ni, Yun Liu, Yue Tang*, Jing Chen, Shuhan Li, Ji Pu, Lidong Han. GABAB receptor ligand-directed trimethyl chitosan/tripolyphosphate nanoparticles and their pMDI formulation for survivin siRNA pulmonary delivery [J]. Carbohydrate Polymers, 2018, 179: 135-144.
5. Jing Chen, Yue Tang*, Yun Liu, Yushun Dou. Nucleic Acid-Based Therapeutics for Pulmonary Diseases[J].AAPS PharmSciTech,2018,19(8):3670-3680.
6. Suhui Ni, Yuwen Xie, Yue Tang*, Yun Liu, Jing Chen, Siyan Zhu. Nebulized anionic guanidinylated O-carboxymethyl chitosan/N-2-hydroxypropyltimehyl ammonium chloride chitosan nanoparticles for siRNA pulmonary delivery: preparation, characterization and in vitro evaluation[J]. Journal of Drug Targeting, 2017, 25(5):451-462.
7. Heyang Zhang, Yuwen Xie, Yue Tang*, Suhui Ni, Bo Wang, Zhen Chen, Xuejing Liu. Development and characterization of thermo-sensitive films containing asiaticoside based on polyvinyl alcohol and Methylcellulose[J]. Journal of Drug Delivery Science & Technology, 2015, 30:133-145.
8. Liqun Jiang, Yue Tang*, Hongjiu Zhang, Xifeng Lu, Xijing Chen, Jiabi Zhu. Importance of Powder Residence Time for the Aerosol Delivery Performance of a Commercial Dry Powder Inhaler Aerolizer (R) [J]. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2012, 25(5): 265-279.
9. Yue Tang*, Heyang Zhang, Xifeng Lu, Liqun Jiang, Xinyuan Xi, Jianping Liu, and Jiabi Zhu. Development and evaluation of a dry powder formulation of liposome-encapsulated oseltamivir phosphate for inhalation [J]. Drug Delivery, 2015;22(5):608-18. doi: 10.3109/10717544.2013.863526. Epub 2013 Dec 4.2015.
10. Yue Tang, Jiabi Zhu. Recombinant human interleukin-2 inhalation powders: Preparation and distribution in the alveolus [J]. International Journal of Pharmaceutics, 2008, 360(1-2): 225-227.
